// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Reduced lung function and cognitive decline in ageing: a longitudinal cohort study

Wuxiang Xie - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Use of NEWS2 to predict length of stay and in hospital mortality at exacerbation of COPD

Philip Stone - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Lung function curve over the life-course using longitudinal data from multiple cohorts

Judith Garcia Aymerich - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

External validation of two prognostic scores predicting exacerbations in ECLIPSE COPD patients

Spencer Keene - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis

Rupert Jakes - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes (TORPEDO: a modified Delphi exercise to identify a core dataset for asthma and COPD studies

Job Van Boven - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Comparison of five major airflow limitation criteria to identify high-risk individuals with COPD in the general population

Yunus Çolak - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Trends of asthma incidence over 80 years in Europe: preliminary results from the Ageing Lungs in European Cohorts (ALEC study

Simone Accordini - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

European Trends in Chronic Obstructive Pulmonary Disease Mortality and Incidence rates 2001 to 2017

Dominic Marshall - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Prevalence of COPD in Nepal: findings from a community-based study >

Tara Ballav Adhikari - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Long-term trends in lung cancer incidence in non-smokers: a UK-based cohort study of 3.7 million people

Laura Horsfall - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

The mediating role of C-reactive protein (CRP and insulin resistance in the association of mid-childhood fat mass and airflow limitation at 15 years

Gabriela P. Peralta - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Experience of measuring nasal nitric oxide (nNO in a National Primary Ciliary Dyskinesia (PCD Centre (2006-20

Amanda Harris - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Primary ciliary dyskinesia

Nitric oxide

Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries

Cristina Rebordosa - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

LAS 34273

Inhaled Corticosteroids and Risk of Osteoporosis in Late-Middle Age Subjects: A Multicenter European Cohort Study

Amelia Grosso - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

Implications of different CT emphysema thresholds on COPD phenotypes

Christina Due Svendsen - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Presentation and management of primary and secondary spontaneous pneumothoraces in Ayrshire, a semi-rural population health district - a 5-year retrospective study, 2014 to 2018

Lorna Stillie - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Risk factors for low forced vital capacity in the multinational BOLD study: An update

Andre F.S. Amaral - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Life-course socioeconomic disadvantage and respiratory-related functioning lost in older adults: a multi-cohort study of 53 788 individuals

Vânia Rocha - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Investigating the Respiratory therapist perception of committed medical incidents in Intensive care unit (ICU

Abdullah AlQahtani - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved